- Home
- GDEN vs NTLA Comparison
GDEN vs NTLA Comparison
Compare GDEN & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEN
- NTLA
- Stock Information
- Founded
- GDEN 1998
- NTLA 2014
- Country
- GDEN United States
- NTLA United States
- Employees
- GDEN N/A
- NTLA N/A
- Industry
- GDEN Services-Misc. Amusement & Recreation
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GDEN Consumer Discretionary
- NTLA Health Care
- Exchange
- GDEN Nasdaq
- NTLA Nasdaq
- Market Cap
- GDEN 705.7M
- NTLA 710.1M
- IPO Year
- GDEN 1999
- NTLA 2016
- Fundamental
- Price
- GDEN $27.32
- NTLA $8.12
- Analyst Decision
- GDEN Strong Buy
- NTLA Buy
- Analyst Count
- GDEN 7
- NTLA 19
- Target Price
- GDEN $36.86
- NTLA $38.26
- AVG Volume (30 Days)
- GDEN 152.9K
- NTLA 3.1M
- Earning Date
- GDEN 05-08-2025
- NTLA 05-08-2025
- Dividend Yield
- GDEN 3.85%
- NTLA N/A
- EPS Growth
- GDEN N/A
- NTLA N/A
- EPS
- GDEN 0.39
- NTLA N/A
- Revenue
- GDEN $653,614,000.00
- NTLA $45,569,000.00
- Revenue This Year
- GDEN $2.32
- NTLA N/A
- Revenue Next Year
- GDEN $2.80
- NTLA N/A
- P/E Ratio
- GDEN $66.78
- NTLA N/A
- Revenue Growth
- GDEN N/A
- NTLA N/A
- 52 Week Low
- GDEN $22.66
- NTLA $5.90
- 52 Week High
- GDEN $35.49
- NTLA $28.18
- Technical
- Relative Strength Index (RSI)
- GDEN 58.80
- NTLA 50.39
- Support Level
- GDEN $25.28
- NTLA $7.21
- Resistance Level
- GDEN $26.67
- NTLA $9.27
- Average True Range (ATR)
- GDEN 0.85
- NTLA 0.61
- MACD
- GDEN 0.20
- NTLA 0.02
- Stochastic Oscillator
- GDEN 83.40
- NTLA 44.20
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.